These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30747998)

  • 21. The role of HSP27 in the development of drug resistance of gastrointestinal malignancies: Current status and perspectives.
    Soleimani A; Jalili-Nik M; Avan A; Ferns GA; Khazaei M; Hassanian SM
    J Cell Physiol; 2019 Jun; 234(6):8241-8248. PubMed ID: 30471115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenase-2 expression in stromal tumors of the gastrointestinal tract.
    Sheehan KM; Sabah M; Cummins RJ; O'Grady A; Murray FE; Leader MB; Kay EW
    Hum Pathol; 2003 Dec; 34(12):1242-6. PubMed ID: 14691908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.
    Abdel-Rahman O
    Tumour Biol; 2015 Jan; 36(1):21-31. PubMed ID: 25394897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autophagy-related microRNAs: Possible regulatory roles and therapeutic potential in and gastrointestinal cancers.
    Pourhanifeh MH; Vosough M; Mahjoubin-Tehran M; Hashemipour M; Nejati M; Abbasi-Kolli M; Sahebkar A; Mirzaei H
    Pharmacol Res; 2020 Nov; 161():105133. PubMed ID: 32822869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.
    Berretta M; Romano C; Di Francia R; De Diviitis C; Canzonieri V; Caraglia M; Facchini G; Nasti G
    Curr Cancer Drug Targets; 2018; 18(5):430-441. PubMed ID: 28183250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides.
    Soliman E; Henderson KL; Danell AS; Van Dross R
    Mol Carcinog; 2016 Feb; 55(2):117-30. PubMed ID: 25557612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphenol A-induced epithelial to mesenchymal transition is mediated by cyclooxygenase-2 up-regulation in human endometrial carcinoma cells.
    Wang KH; Kao AP; Chang CC; Lin TC; Kuo TC
    Reprod Toxicol; 2015 Dec; 58():229-33. PubMed ID: 26546977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Importance of Cancer Stem Cells in Gastrointestinal Cancers.
    Dindar DA; Albayrak G; Ozet A
    Crit Rev Oncog; 2019; 24(1):55-59. PubMed ID: 31679220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies: focus on a new strategy for gastrointestinal tumors.
    Nicolella D; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2003 Sep; 47(3):261-71. PubMed ID: 12962900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.
    Panza E; De Cicco P; Ercolano G; Armogida C; Scognamiglio G; Anniciello AM; Botti G; Cirino G; Ianaro A
    Oncotarget; 2016 Aug; 7(35):57077-57085. PubMed ID: 27494851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 32. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells.
    Stasinopoulos I; O'Brien DR; Wildes F; Glunde K; Bhujwalla ZM
    Mol Cancer Res; 2007 May; 5(5):435-42. PubMed ID: 17510310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
    Kourie HR; Tabchi S; Ghosn M
    World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 as a target for anticancer drug development.
    Méric JB; Rottey S; Olaussen K; Soria JC; Khayat D; Rixe O; Spano JP
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):51-64. PubMed ID: 16531064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of the S1P
    Filipenko I; Schwalm S; Reali L; Pfeilschifter J; Fabbro D; Huwiler A; Zangemeister-Wittke U
    Biochim Biophys Acta; 2016 Nov; 1861(11):1840-1851. PubMed ID: 27616330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
    Liu XH; Kirschenbaum A; Yao S; Stearns ME; Holland JF; Claffey K; Levine AC
    Clin Exp Metastasis; 1999; 17(8):687-94. PubMed ID: 10919714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
    Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
    Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer.
    Wang D; Cabalag CS; Clemons NJ; DuBois RN
    Gastroenterology; 2021 Dec; 161(6):1813-1829. PubMed ID: 34606846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approach to angiogenesis inhibition based on cyclooxygenase-2.
    Masferrer J
    Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential and rationale for COX-2 inhibitors in lung cancer.
    Krysan K; Reckamp KL; Sharma S; Dubinett SM
    Anticancer Agents Med Chem; 2006 May; 6(3):209-20. PubMed ID: 16712449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.